Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

New and emerging targeted treatments in advanced non-small-cell lung cancer

(2016) Fred R Hirsch et al.   LANCET

PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression

(2016) Dai Horiuchi et al.   NATURE MEDICINE

Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B

(2015) M. K. Kashyap et al.   HAEMATOLOGICA

Myc protein expression correlates withMYCamplification in small-cell lung carcinoma

(2015) David H Hwang et al.   HISTOPATHOLOGY

The spliceosome is a therapeutic vulnerability in MYC-driven cancer

(2015) Tiffany Y.-T. Hsu et al.   NATURE

MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis

(2015) Cheryl M. Koh et al.   NATURE

MYC is a critical target of FBXW7

(2015) Mai Sato et al.   Oncotarget

Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B

(2015) M. K. Kashyap et al.   HAEMATOLOGICA

Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening

(2014) Zongxiang Zhou et al.   BMC CANCER

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

(2014) Camilla L. Christensen et al.   CANCER CELL

Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing

(2014) David G. McFadden et al.   CELL

An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth

(2014) A. S. Adler et al.   GENES & DEVELOPMENT

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor

(2014) Kenichi Suda et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy

(2013) V. Quidville et al.   CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

(2013) F. A. L. M. Eskens et al.   CLINICAL CANCER RESEARCH

Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A

(2013) C. G. Hubert et al.   GENES & DEVELOPMENT

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

(2013) D. S. Hong et al.   INVESTIGATIONAL NEW DRUGS

Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells

(2012) Buntitabhon Sirichanchuen et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

(2012) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

(2011) J. D. Kessler et al.   SCIENCE